Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRD119
MIFTS: 66

Cardiac Arrest

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cardiac Arrest

About this section

MalaCards integrated aliases for Cardiac Arrest:

Name: Cardiac Arrest 12 77 30 56 6 44 15 17 74
Cardiopulmonary Arrest 12 56 74
Circulatory Arrest 12 15 74
Heart Arrest 45

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060319
ICD9CM 36 427.5
MeSH 45 D006323
SNOMED-CT 69 30298009
ICD10 34 I46 I46.0
Sources

Summaries for Cardiac Arrest

About this section
MedlinePlus : 44 The heart has an internal electrical system that controls the rhythm of the heartbeat. Problems can cause abnormal heart rhythms, called arrhythmias. There are many types of arrhythmia. During an arrhythmia, the heart can beat too fast, too slow, or it can stop beating. Sudden cardiac arrest (SCA) occurs when the heart develops an arrhythmia that causes it to stop beating. This is different than a heart attack, where the heart usually continues to beat but blood flow to the heart is blocked. There are many possible causes of SCA. They include coronary heart disease, physical stress, and some inherited disorders. Sometimes there is no known cause for the SCA. Without medical attention, the person will die within a few minutes. People are less likely to die if they have early defibrillation. Defibrillation sends an electric shock to restore the heart rhythm to normal. You should give cardiopulmonary resuscitation (CPR) to a person having SCA until defibrillation can be done. If you have had an SCA, an implantable cardiac defibrillator (ICD) reduces the chance of dying from a second SCA. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Cardiac Arrest, also known as cardiopulmonary arrest, is related to ventricular fibrillation, paroxysmal familial, 1 and arrhythmogenic right ventricular cardiomyopathy, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Cardiac Arrest is PLN (Phospholamban), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Aldosterone synthesis and secretion. The drugs Clonazepam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 A congestive heart failure characterized by a sudden stop in effective blood circulation due to the failure of the heart to contract effectively or at all.

Wikipedia : 77 Cardiac arrest is a sudden loss of blood flow resulting from the failure of the heart to effectively... more...

Sources

Related Diseases for Cardiac Arrest

About this section

Diseases in the Cardiac Arrest family:

Post-Cardiac Arrest Syndrome

Diseases related to Cardiac Arrest via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 ventricular fibrillation, paroxysmal familial, 1 32.6 DSP KCNQ1 RYR2 SCN5A TNNT2
2 arrhythmogenic right ventricular cardiomyopathy 32.5 DSP PLN RYR2 SCN5A
3 cardiac conduction defect 32.1 DSP KCNQ1 MYBPC3 PLN RYR2 SCN5A
4 myocardial infarction 32.0 ACE ALB CKB S100B TNNT2
5 long qt syndrome 1 31.9 CALM1 CALM3 CASQ2 DSP KCNQ1 RYR2
6 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 31.6 CALM1 CASQ2 DSP KCNQ1 RYR2 SCN5A
7 long qt syndrome 30.5 CALM1 CALM3 KCNQ1 MYBPC3 RYR2 SCN5A
8 cardiac arrhythmia 30.5 KCNQ1 RYR2 SCN5A
9 atrial standstill 1 30.4 ACE DSP MYBPC3 PLN SCN5A SLC25A20
10 atrial fibrillation 30.3 ACE KCNQ1 MYBPC3 RYR2 SCN5A
11 hypertrophic cardiomyopathy 30.3 ACE DSP MYBPC3 PLN RYR2 SCN5A
12 neonatal hypoxic and ischemic brain injury 30.2 CKB ENO2
13 catecholaminergic polymorphic ventricular tachycardia 30.2 CALM1 CALM3 CASQ2 DSP MYBPC3 RYR2
14 middle cerebral artery infarction 29.8 ENO2 S100B
15 heart disease 29.8 ACE ALB DSP KCNQ1 MYBPC3 RYR2
16 left ventricular noncompaction 29.7 DSP KCNQ1 MYBPC3 RYR2 SCN5A TNNT2
17 dilated cardiomyopathy 29.2 ACE ALB DSP KCNQ1 MYBPC3 PLN
18 post-cardiac arrest syndrome 12.5
19 jervell and lange-nielsen syndrome 1 11.5
20 hypoxia 11.4
21 hypokalemia 11.4
22 myocarditis 11.4
23 orthostatic intolerance 11.4
24 pulmonary edema 11.4
25 cerebral hypoxia 11.4
26 wolff-parkinson-white syndrome 11.4
27 eclampsia 11.3
28 cyanide poisoning 11.3
29 cardiomyopathy, infantile histiocytoid 11.3
30 ventricular tachycardia, catecholaminergic polymorphic, 3 11.2
31 coronary artery dissection, spontaneous 11.0
32 pseudohyperkalemia, familial, 2, due to red cell leak 11.0
33 ventricular tachycardia, catecholaminergic polymorphic, 2 11.0
34 ventricular tachycardia, catecholaminergic polymorphic, 4 11.0
35 ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness 11.0
36 sudden cardiac failure, infantile 11.0
37 sudden cardiac failure, alcohol-induced 11.0
38 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.5 DSP RYR2
39 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.5 DSP RYR2
40 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.5 DSP RYR2
41 pulmonary embolism 10.5
42 long qt syndrome 15 10.5 CALM1 CALM3
43 ocular motor apraxia 10.5
44 ischemia 10.5
45 otomycosis 10.5 CALM1 CALM3
46 intracranial cysts 10.4 ENO2 S100B
47 bednar tumor 10.4 ENO2 S100B
48 external ear disease 10.4 CALM1 CALM3
49 emery-dreifuss muscular dystrophy 5, autosomal dominant 10.4 CALM1 CALM3
50 arrhythmogenic right ventricular dysplasia, familial, 9 10.4 DSP PLN RYR2

Comorbidity relations with Cardiac Arrest via Phenotypic Disease Network (PDN): (show all 33)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Aortic Aneurysm Aortic Valve Disease 1
Bronchitis Cardiogenic Shock
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Disseminated Intravascular Coagulation Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Intermediate Coronary Syndrome
Ischemic Heart Disease Kidney Disease
Mitral Valve Disease Ocular Motor Apraxia
Peripheral Vascular Disease Progressive Familial Heart Block, Type Ia
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Respiratory Failure Sinoatrial Node Disease
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiac Arrest:



Diseases related to Cardiac Arrest
Sources

Symptoms & Phenotypes for Cardiac Arrest

About this section

UMLS symptoms related to Cardiac Arrest:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Cardiac Arrest:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 ACE AVP CKB CYCS ENO2 KCNQ1
2 cardiovascular system MP:0005385 9.85 ACE CASQ2 CYCS DSP KCNQ1 MYBPC3
3 growth/size/body region MP:0005378 9.7 ACE CASQ2 CKB CYCS DSP ENO2
4 muscle MP:0005369 9.28 ALB CASQ2 DSP KCNQ1 MYBPC3 RYR2
Sources

Drugs & Therapeutics for Cardiac Arrest

About this section

Drugs for Cardiac Arrest (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 780)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
4
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
5
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
7
Ticagrelor Approved Phase 4 274693-27-5 9871419
8
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
9
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 113775-47-6 68602 5311068
10
Midazolam Approved, Illicit Phase 4,Phase 3,Not Applicable 59467-70-8 4192
11
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
12
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
13
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
14
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
16 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7681-49-4
17
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
19
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
20
Cisatracurium Approved Phase 4 96946-41-7
21
Misoprostol Approved Phase 4,Phase 1 59122-46-2 5282381
22
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
23
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
24
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
25
Mannitol Approved, Investigational Phase 4,Phase 2,Not Applicable 69-65-8 453 6251
26
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
28
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
29
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 59-42-7 6041
30
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1491-59-4 4636
31
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-56-6 439302 53477758
32
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
33
Nitroprusside Approved, Investigational Phase 4,Phase 3 15078-28-1 11963622
34
Clavulanate Approved, Vet_approved Phase 4,Phase 3 58001-44-8 5280980
35
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
36
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
37
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
38
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
39
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
40
Clopidogrel Approved Phase 4,Not Applicable 120202-66-6, 113665-84-2 60606
41
Cangrelor Approved Phase 4 163706-06-7 9854012
42
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 16590-41-3 5360515
43
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
44
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
45
Nifedipine Approved Phase 4,Phase 2 21829-25-4 4485
46
Ritodrine Approved, Investigational Phase 4 26652-09-5 33572
47
Sulfamethazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57-68-1 5327
48
Etomidate Approved Phase 4 33125-97-2 36339 667484
49
Atropine Approved, Vet_approved Phase 4,Phase 2 51-55-8, 5908-99-6 174174
50
Meperidine Approved Phase 4 57-42-1 4058

Interventional clinical trials:

(show top 50) (show all 1714)
# Name Status NCT ID Phase Drugs
1 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
2 Hyperinvasive Approach in Cardiac Arrest Unknown status NCT01511666 Phase 4
3 Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
6 Early Feeding Following Ligation of Acute Bleeding Varices Unknown status NCT01287702 Phase 4
7 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
8 Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts Unknown status NCT02341833 Phase 4 Sevoflurane
9 CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis Unknown status NCT02128256 Phase 4
10 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
11 Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery Unknown status NCT02719093 Phase 4 recombinant FSH
12 Safety and Efficacy of Intranasal Dexmedetomidine Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
13 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
14 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
15 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
16 The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation Unknown status NCT02808897 Phase 4
17 Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation Recruiting NCT02750462 Phase 4
18 Prophylactic Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest Completed NCT02899507 Phase 4 Amoxicillin-Clavulanic acid
19 Continuous Chest Compressions vs AHA Standard CPR of 30:2 Completed NCT01372748 Phase 4
20 Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
21 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
22 Intraosseous vs Intravenous Access for Cardiac Arrest Treatment Completed NCT02088736 Phase 4
23 Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients Completed NCT00827957 Phase 4
24 Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study) Completed NCT00392639 Phase 4
25 Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
26 Antiplatelet Therapy After Cardiac Arrest Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
27 COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest Completed NCT00843297 Phase 4
28 Add-on Cangrelor in STEMI-triggered Cardiac Arrest Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
29 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest Completed NCT01369732 Phase 4 recombinant human erythropoietin;saline
30 Cardiopulmonary Resuscitation Witnessing by a Relative Completed NCT01009606 Phase 4
31 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
32 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
33 Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? Completed NCT00180362 Phase 4
34 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
35 Epinephrine Dose: Optimal Versus Standard Evaluation Trial Not yet recruiting NCT03826524 Phase 4 Epinephrine
36 Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor Recruiting NCT02430233 Phase 4 micronized progesterone 400 mg (Utrogestan)
37 Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension Completed NCT02265965 Phase 4 intravenous nitroglycerin
38 Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial Recruiting NCT02678728 Phase 4 Dexmedetomidine;normal saline
39 Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR Terminated NCT01718795 Phase 4
40 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
41 Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion Completed NCT00454428 Phase 4
42 Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor Completed NCT03040752 Phase 4 Nifedipine 20 Mg;Ritodrine Oral Tablet
43 Comparison of Silver Modified and Conventional Atraumatic Restorative Treatment Modalities Not yet recruiting NCT03881020 Phase 4 Silver diamine Fluoride 38%
44 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
45 Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial Recruiting NCT02643381 Phase 4 Etomidate;Ketamine
46 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
47 Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation Recruiting NCT03787732 Phase 4 Fluid Bolus
48 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed NCT00430989 Phase 4 Nitrous Oxide;Nitrous Oxide
49 IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis Terminated NCT00774631 Phase 4
50 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone

Search NIH Clinical Center for Cardiac Arrest

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: heart arrest

Sources

Genetic Tests for Cardiac Arrest

About this section

Genetic tests related to Cardiac Arrest:

# Genetic test Affiliating Genes
1 Cardiac Arrest 30
Sources

Anatomical Context for Cardiac Arrest

About this section

MalaCards organs/tissues related to Cardiac Arrest:

42
Heart, Brain, Kidney, Breast, Lung, Testes, Bone
Sources

Publications for Cardiac Arrest

About this section

Articles related to Cardiac Arrest:

(show top 50) (show all 4363)
# Title Authors Year
1
Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab. ( 30680669 )
2019
2
Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ( 30799546 )
2019
3
Cardiac arrest as an age-dependent prognosticator for long-term mortality after acute myocardial infarction: the potential impact of infarction size. ( 29856229 )
2019
4
The Acute Respiratory Distress Syndrome after Out-of-Hospital Cardiac Arrest: Incidence, Risk Factors, and Outcomes. ( 30654012 )
2019
5
Depression and anxiety in relatives of out-of-hospital cardiac arrest patients: Results of a prospective observational study. ( 30745287 )
2019
6
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. ( 30874766 )
2019
7
Reply to: Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878373 )
2019
8
Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878376 )
2019
9
The Burden of Brain Hypoxia and Optimal Mean Arterial Pressure in Patients With Hypoxic Ischemic Brain Injury After Cardiac Arrest. ( 30889022 )
2019
10
A comparison of non-invasive versus invasive measures of intracranial pressure in hypoxic ischaemic brain injury after cardiac arrest. ( 30629992 )
2019
11
Prevalence of spontaneous type I ECG pattern, syncope, and other risk markers in sudden cardiac arrest survivors with Brugada syndrome. ( 30569504 )
2019
12
Sudden cardiac arrest and Brugada syndrome: The search is on for better risk stratification. ( 30569570 )
2019
13
Timing of Advanced Airway Placement after Witnessed Out-of-Hospital Cardiac Arrest. ( 30912467 )
2019
14
In-Hospital Cardiac Arrest: A Review. ( 30912843 )
2019
15
Update: Focus In-hospital maternal cardiac arrest. ( 30796984 )
2019
16
Prognostic performance of simplified out-of-hospital cardiac arrest (OHCA) and cardiac arrest hospital prognosis (CAHP) scores in an East Asian population: a prospective cohort study. ( 30797049 )
2019
17
Timing of in-hospital cardiac arrest after pediatric cardiac surgery: An important metric for quality improvement and prognostication? ( 30797581 )
2019
18
The Additive Effect of Atropine Sulfate during Cardiopulmonary Resuscitation in Out-of-hospital Non-traumatic Cardiac Arrest patients with Non-shockable Rhythm. ( 30799340 )
2019
19
Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter? ( 30799547 )
2019
20
Successful Defibrillation of Four Hypothermic Patients with Witnessed Cardiac Arrest. ( 30801202 )
2019
21
Relationship between socioeconomic factors, distribution of public access defibrillators and incidence of out-of-hospital cardiac arrest. ( 30802556 )
2019
22
Relationship between institutional case volume and one-month survival among cases of paediatric out-of-hospital cardiac arrest. ( 30802557 )
2019
23
Atlanto-occipital dislocation in a patient presenting with out-of-hospital cardiac arrest: a case report and literature review. ( 30803441 )
2019
24
Polycythemia Vera Presenting as Cardiac Arrest: Novel Management Strategies. ( 30805220 )
2019
25
Cardiac Arrest Outcomes in Children With Preexisting Neurobehavioral Impairment. ( 30807545 )
2019
26
Ion shift index as a promising prognostic indicator in adult patients resuscitated from cardiac arrest. ( 30807816 )
2019
27
Neutrophil-lymphocyte ratio: A prognostic tool in patients with in-hospital cardiac arrest. ( 30815378 )
2019
28
Imbalance of angiotensin-converting enzymes affects myocardial apoptosis during cardiac arrest induced by acute pulmonary embolism in a porcine model. ( 30816437 )
2019
29
Aortic Stenosis is an Independent Predictor for Outcome in Patients with In-Hospital Cardiac Arrest. ( 30818015 )
2019
30
Increasing cardiac arrest survivor access to advanced neuromonitoring and neuroprognostication, as recommended in international guidelines - A pilot study. ( 30818017 )
2019
31
Why did this patient experience a sudden cardiac arrest? Follow your curiosity! ( 30818094 )
2019
32
Association of extracerebral organ failure with 1-year survival and healthcare-associated costs after cardiac arrest: an observational database study. ( 30819234 )
2019
33
Derivation and Validation of the SWAP Score for Very Early Prediction of Neurologic Outcome in Patients With Out-of-Hospital Cardiac Arrest. ( 30819521 )
2019
34
Pre-hospital advanced airway management for adults with out-of-hospital cardiac arrest: nationwide cohort study. ( 30819685 )
2019
35
Two-site regional oxygen saturation and capnography monitoring during resuscitation after cardiac arrest in a swine pediatric ventricular fibrillatory arrest model. ( 30820870 )
2019
36
Experience of extracorporeal cardiopulmonary resuscitation in a refractory cardiac arrest patient at the emergency department. ( 30820972 )
2019
37
Association between left ventricular outflow tract opening and successful resuscitation after cardiac arrest. ( 30825552 )
2019
38
Mechanism and extent of myocardial injury associated with out-of-hospital cardiac arrest. ( 30826528 )
2019
39
Aspirin Use to Reduce the Risk of Sports-Related Cardiac Arrest in High-Risk Athletes. ( 30827346 )
2019
40
Outcomes From Brain Death Donors With Previous Cardiac Arrest Accepted for Pancreas Transplantation: A Single-center Retrospective Analysis. ( 30829695 )
2019
41
Pediatric In-Hospital Cardiac Arrest-Can We Do Better? ( 30830019 )
2019
42
A Rare Cause of Cardiac Arrest in the Era of Genetic Testing. ( 30830022 )
2019
43
Outcome after pre-hospital cardiac arrest in accordance with underlying cause. ( 30831217 )
2019
44
Hypoxic liver injury after in- and out-of-hospital cardiac arrest: Risk factors and neurological outcome. ( 30831218 )
2019
45
Usefulness of a quantitative analysis of the cerebrospinal fluid volume proportion in brain computed tomography for predicting neurological prognosis in cardiac arrest survivors who undergo target temperature management. ( 30831551 )
2019
46
Value of capnography to predict defibrillation success in out-of-hospital cardiac arrest. ( 30836170 )
2019
47
Early withdrawal of life support after resuscitation from cardiac arrest is common and may result in additional deaths. ( 30836171 )
2019
48
In Reply: "Impact of Targeted Temperature Management on ED Patients with Drug Overdose-Related Cardiac Arrest". ( 30838508 )
2019
49
Cardiac Arrest in Special Circumstances-Recent Advances in Resuscitation. ( 30839376 )
2019
50
Cerebral oximetry in cardiac arrest: a potential role but with limitations. ( 30840118 )
2019
Sources

Variations for Cardiac Arrest

About this section

ClinVar genetic disease variations for Cardiac Arrest:

6 (show top 50) (show all 70)
# Gene Variation Type Significance SNP ID Assembly Location
1 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh38 Chromosome 1, 237792300: 237792300
2 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh37 Chromosome 1, 237955600: 237955600
3 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh37 Chromosome 4, 114275980: 114275980
4 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh38 Chromosome 4, 113354824: 113354824
5 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh37 Chromosome 6, 7574448: 7574448
6 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh38 Chromosome 6, 7574215: 7574215
7 DSP NM_004415.3(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh38 Chromosome 6, 7576986: 7576986
8 DSP NM_004415.3(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh37 Chromosome 6, 7577219: 7577219
9 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh38 Chromosome 7, 81969925: 81969925
10 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh37 Chromosome 7, 81599241: 81599241
11 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh37 Chromosome 7, 91630330: 91630330
12 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh38 Chromosome 7, 92001016: 92001016
13 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh37 Chromosome 7, 91735039: 91735039
14 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh38 Chromosome 7, 92105725: 92105725
15 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh37 Chromosome 10, 18823159: 18823159
16 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh38 Chromosome 10, 18534230: 18534230
17 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh37 Chromosome 10, 18828312: 18828312
18 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh38 Chromosome 10, 18539383: 18539383
19 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh37 Chromosome 14, 23855770: 23855770
20 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh38 Chromosome 14, 23386561: 23386561
21 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh37 Chromosome 18, 29110998: 29110998
22 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh38 Chromosome 18, 31531035: 31531035
23 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic rs111033560 GRCh37 Chromosome 6, 118880200: 118880200
24 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic rs111033560 GRCh38 Chromosome 6, 118559037: 118559037
25 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh37 Chromosome 11, 47354463: 47354463
26 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh38 Chromosome 11, 47332912: 47332912
27 DSG2 NM_001943.3(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh37 Chromosome 18, 29101120: 29101120
28 DSG2 NM_001943.3(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh38 Chromosome 18, 31521157: 31521157
29 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Likely benign rs139399951 GRCh37 Chromosome 18, 28662896: 28662896
30 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Likely benign rs139399951 GRCh38 Chromosome 18, 31082930: 31082930
31 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh37 Chromosome 2, 179571371: 179571371
32 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh38 Chromosome 2, 178706644: 178706644
33 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh37 Chromosome 3, 38645378: 38645378
34 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh38 Chromosome 3, 38603887: 38603887
35 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh37 Chromosome 1, 237532902: 237532902
36 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh38 Chromosome 1, 237369602: 237369602
37 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh37 Chromosome 3, 38592788: 38592788
38 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh38 Chromosome 3, 38551297: 38551297
39 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh38 Chromosome 3, 38620895: 38620895
40 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh37 Chromosome 3, 38662386: 38662386
41 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh38 Chromosome 3, 57912702: 57912702
42 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh37 Chromosome 3, 57898429: 57898429
43 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh37 Chromosome 4, 114275283: 114275283
44 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh38 Chromosome 4, 113354127: 113354127
45 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh37 Chromosome 4, 114277232: 114277232
46 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh38 Chromosome 4, 113356076: 113356076
47 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh37 Chromosome 4, 114277351: 114277351
48 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh38 Chromosome 4, 113356195: 113356195
49 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh37 Chromosome 6, 7572218: 7572218
50 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh38 Chromosome 6, 7571985: 7571985
Sources

Expression for Cardiac Arrest

About this section
Search GEO for disease gene expression data for Cardiac Arrest.
Sources

Pathways for Cardiac Arrest

About this section

Pathways related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds 67
Show member pathways
 13.22 ALB AVP CALM1 CALM3 PLN RYR2
2
Aldosterone synthesis and secretion 38
Show member pathways
 12.62 ALB CALM1 CALM3 KCNQ1 PLN RYR2
3
Neuroscience 4
12.41 AVP CALM1 ENO2 S100B SCN5A
4
Ion channel transport 67
Show member pathways
 12.35 CALM1 CALM3 PLN RYR2 TRDN
5
Cardiac conduction 67
Show member pathways
 12.34 CALM1 CALM3 KCNQ1 MYBPC3 PLN RYR2
6
DREAM Repression and Dynorphin Expression 65
Show member pathways
 12.33 CALM1 CALM3 CYCS RYR2
7
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.32 CALM1 CALM3 CASQ2 PLN RYR2
8
cAMP signaling pathway 38
12.15 CALM1 CALM3 PLN RYR2
9
Calcium signaling pathway 38
12.09 CALM1 CALM3 PLN RYR2
10
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.01 AVP KCNQ1 RYR2 SCN5A
11
Dilated cardiomyopathy (DCM) 38
Show member pathways
 11.9 ACE MYBPC3 PLN RYR2 TNNT2
12
Ca, cAMP and Lipid Signaling 4
11.77 ALB CALM1 PLN S100B
13
Renin secretion 38
11.55 ACE CALM1 CALM3
14
Phase 0 - rapid depolarisation 67
Show member pathways
 11.5 CALM1 CALM3 KCNQ1 SCN5A
15
Nur77 Signaling in T-Cell 65
11.12 CALM1 CALM3 CYCS
16
Antiarrhythmic Pathway, Pharmacodynamics 62
10.85 CASQ2 DSP KCNQ1 PLN RYR2 SCN5A
17
RHO GTPases activate IQGAPs 67
10.67 CALM1 CALM3
Sources

GO Terms for Cardiac Arrest

About this section

Cellular components related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.72 ALB CALM1 CALM3 CKB ENO2
2 Z disc GO:0030018 9.71 CASQ2 MYBPC3 RYR2 SCN5A
3 sarcoplasmic reticulum GO:0016529 9.67 CASQ2 PLN RYR2 TRDN
4 catalytic complex GO:1902494 9.49 CALM1 CALM3
5 sarcoplasmic reticulum lumen GO:0033018 9.48 CASQ2 TRDN
6 cardiac myofibril GO:0097512 9.46 MYBPC3 TNNT2
7 sarcoplasmic reticulum membrane GO:0033017 9.46 CASQ2 PLN RYR2 TRDN
8 junctional membrane complex GO:0030314 9.43 CASQ2 TRDN
9 junctional sarcoplasmic reticulum membrane GO:0014701 9.43 CASQ2 RYR2 TRDN
10 calcium channel complex GO:0034704 9.26 CALM1 CALM3 CASQ2 RYR2
11 sarcomere GO:0030017 9.02 CALM1 CALM3 MYBPC3 RYR2 TNNT2

Biological processes related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.86 PLN RYR2 TRDN
2 calcium-mediated signaling GO:0019722 9.85 CALM1 CALM3 RYR2
3 muscle contraction GO:0006936 9.84 CALM1 MYBPC3 TNNT2 TRDN
4 ion transmembrane transport GO:0034220 9.83 CASQ2 KCNQ1 RYR2 SCN5A TRDN
5 response to calcium ion GO:0051592 9.81 CALM1 CALM3 TNNT2
6 substantia nigra development GO:0021762 9.77 CALM1 CALM3 CKB
7 regulation of cardiac conduction GO:1903779 9.76 CASQ2 RYR2 TRDN
8 sarcomere organization GO:0045214 9.75 CASQ2 MYBPC3 TNNT2
9 regulation of heart contraction GO:0008016 9.74 KCNQ1 PLN TNNT2
10 regulation of heart rate by cardiac conduction GO:0086091 9.73 DSP KCNQ1 SCN5A
11 negative regulation of peptidyl-threonine phosphorylation GO:0010801 9.69 CALM1 CALM3
12 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.69 CALM1 CALM3
13 heart contraction GO:0060047 9.68 ACE TRDN
14 cellular response to epinephrine stimulus GO:0071872 9.68 KCNQ1 RYR2
15 negative regulation of ATPase activity GO:0032780 9.68 PLN TNNT2
16 regulation of cardiac muscle cell contraction GO:0086004 9.67 PLN SCN5A
17 regulation of membrane repolarization GO:0060306 9.67 CASQ2 KCNQ1
18 regulation of cardiac muscle contraction